Table of contents
Expand All Topics
Juvenile idiopathic arthritis-associated uveitis
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of juvenile idiopathic arthritis-associated uveitis are prepared by our editorial team based on guidelines from the Arthritis Foundation (AF/ACR 2019), the German Society of Pediatric Rheumatology (GKJR/BVA/DGRh/DOG 2019), and the Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE initiative 2018).
1
2
3
Screening and diagnosis
Classification and risk stratification
Medical management
General principles: as per BVA/DGRh/DOG/GKJR 2019 guidelines, initiate treatment in patients with JIA-associated active uveitis.
E
More topics in this section
Topical corticosteroids
DMARDs (conventional DMARDs)
DMARDs (biological DMARDs)
Systemic corticosteroids
NSAIDs
Cycloplegics
Therapeutic procedures
Ocular corticosteroid injections: as per BVA/DGRh/DOG/GKJR 2019 guidelines, consider administering ocular corticosteroid injections as rescue therapy in individual patients with unilateral or bilateral severe active uveitis with prognostic risk factors for impending uveitis-related deterioration of vision (such as hypotony, macular edema, or dense vitreous opacities), after exhaustion of all other treatment options.
E
Patient education
Follow-up and surveillance
Assessment of treatment response: as per ACR/AF 2019 guidelines, obtain ophthalmic monitoring within 1 month after each change of topical corticosteroids in patients with controlled uveitis tapering or discontinuing topical corticosteroids.
B
Show 2 more
More topics in this section
Treatment tapering